2014 Grant Recipient Gina DeNicola, PhD

Home Research Research Grants Program Grants Awarded Grants Awarded by Year 2014 Pancreatic Cancer Action Network Research Grants 2014 Grant Recipient Gina DeNicola, PhD

GRANTEE: Gina DeNicola, PhD
Institution: Weill Medical College of Cornell University
Research Project: Therapeutic targeting of NRF2-regulated metabolism in pancreatic cancer
Award: 2014 Pancreatic Cancer Action Network – AACR Pathway to Leadership Grant
Award Period: July 1, 2014 – June 30, 2019
Amount: $600,000

Click here to download Dr. DeNicola’s Grant Snapshot (pdf)

Biographical Highlights
Dr. DeNicola is a postdoctoral fellow in the laboratory of Lewis Cantley, PhD. Dr. Cantley is also the co-principal investigator for a 2014 Research Acceleration Network Grant. In addition, another postdoctoral fellow in Dr. Cantley’s lab, Costas Lyssiotis, PhD, received a Pathway to Leadership Grant from the Pancreatic Cancer Action Network in 2013. Dr. DeNicola obtained a bachelor’s degree in biochemistry and molecular biology at the Pennsylvania State University and a doctoral degree in cell and molecular biology at the University of Pennsylvania. Dr. DeNicola’s graduate studies took place in the lab of David Tuveson, MD, PhD, recipient of a 2003 Career Development Award and member of the Pancreatic Cancer Action Network’s Emeritus Scientific Advisory Board.

During her graduate years in the lab of Dr. Tuveson, Dr. DeNicola identified and characterized the regulation of the NRF2 transcription factor by the oncogene K-RAS in mouse models of pancreatic cancer and human tumor samples. She then joined the lab of Dr. Cantley to study the regulation of cellular metabolism by NRF2 and the therapeutic implications of inhibition of NRF2-regulated metabolism for the treatment of cancers with high NRF2 activity.

Project Overview
Dr. DeNicola’s research focuses on a protein called NRF2. NRF2 is a transcription factor, which means that its role is to regulate expression of specific genes within a cell. Dr. DeNicola’s previous work showed that NRF2 is activated by mutant K-RAS in pancreatic cancer cells. Among other functions, NRF2 has been shown to be involved in metabolic pathways in the cell – ways in which nutrients are broken down to provide energy for cellular functions. NRF2 stimulates the breakdown of sugar into molecules called amino acids (serine and glycine) that are building blocks for proteins.

Dr. DeNicola’s project, which will span the remainder of her training in Dr. Cantley’s lab and then continue as she transitions into an independent position, will focus on gaining a deeper understanding of the biology of NRF2 activity in pancreatic cancer cells. She will determine whether protein components or by-products of the pathway could be useful as biomarkers of disease, and/or whether the metabolic process driven by NRF2 could be inhibited as a strategy to block pancreatic cancer growth. Overall, these studies could improve the understanding, detection and treatment of pancreatic cancer.

Wage Hope With Us

Join us to make a difference for pancreatic cancer patients.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2020 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.